Therefore, for patients with PD-L1+ in the advanced stage of NSCLC, combination therapy has become a considerable option, such as the combination of PD-1 monoclonal antibody pembrolizumab with platinum agents' chemotherapy 5. The gene discussed is CD274; the disease is non-small cell lung carcinoma.